logo
New owner plans to transform 68-acre property and horse training facility in Crete into men's rehabilitation center

New owner plans to transform 68-acre property and horse training facility in Crete into men's rehabilitation center

Yahoo29-04-2025

At the end of 2023, after having successfully rehabbed two south west suburban homes into substance use disorder recovery centers through his nonprofit Second Story Foundation, Jim O'Connor said he faced questions of whether he sought to build a facility from scratch.
'I said, 'get me a horse farm and I'll think about it,'' O'Connor recalled.
He just did that March 13, raising $1 million in private donations to acquire a 68-acre harness racing training and horse boarding facility on the corner of East Bemes Road and South Klemme Road in unincorporated Crete.
O'Connor was hard at work Monday at the property, where cart-carrying horses could be seen trotting down a gravel road toward an 85-stall barn.
'I'm here four days a week, and actually working on the site probably 20 hours a week,' O'Connor said.
O'Connor hails from Evanston, but said he fell in love with the south suburbs after entering alcohol abuse recovery in 2016.
It took him losing his relationships — his family, friends and employer — to admit he was an alcoholic, O'Connor said. But once he did, he entered a 28-day, in-patient program in Hazel Crest that eventually led him to the horse farm that inspired him to buy the 2400 East Bemes property.
He said he plans to flip the farm into a picturesque recovery center where up to 14 men can live and work for as long as they need.
'The work-based program was transformational,' O'Connor said. 'The amount of love that I've gotten from people in the recovery community … There's a lot of healthy people with not just lives of dedicated recovery, but full lives based around having made a change in their life.'
On the day the ranch opens and whenever newcomers join the program, selected participants will immediately be told, 'welcome home, we love you,' O'Connor said.
But before that can happen, O'Connor needs to raise funds to build the 7,000-square-foot lodge designed by the Frankfort-based Aspen Group, where residents will stay while they work toward financial, social and physiological independence.
O'Connor envisions the lodge with a large commercial kitchen where his wife, Francie Byrne, will cook and serve two meals a day to residents, as well as a wraparound porch useful for group activities and individual counseling sessions.
O'Connor, Byrne and a few other program leaders will live on the ranch in two staff homes. There are no houses for humans on the property, so these structures will be new.
O'Connor is also looking to state, county and community block grants for the $3.5 million required to get the program on its feet.
'Money drives the timeline,' O'Connor said. 'If the grants line up, we could be building next fall to open this time next year. If the money takes longer, then it takes longer, but we're pretty much shovel ready.'
The Second Story Foundation recently received $88,000 from the Will County Community Mental Health Board toward a community service partnership with the Recovery Community Center of Joliet. It will allow people within Will County Problem Solving Courts satisfy community service requirements by working on the ranch. The service event is scheduled from 8 a.m. to 3 p.m. on May 8 and will include a barbecue lunch and live country music.
O'Connor said the foundation has begun the property zoning process through Will County and is grateful for bipartisan support for the ranch's development.
Unlike many other rehabilitation facilities that accept insurance and out of pocket payments, Second Story Ranch treatment will be free of cost to those who qualify. O'Connor said the program application process involves extensive background checks and interviews to determine its best candidates.
'When you live a life of severe substance use disorder, getting caught up in the legal system and breaking the law is kind of part of it,' O'Connor said. 'We just want to know what the story is.'
Those with long histories of violent crime will not qualify for the program, O'Connor said.
Residents are expected to work on the farm for six to 10 months, the typical phase before they are ready to seek jobs outside the ranch. O'Connor and other program staff will provide connections and support as they transition to a job, and eventually residence, in the broader community.
'In the first phase of the program, we're just working on healing, making human connections, repairing spiritually and building the work ethic,' O'Connor said. 'Once you're working on the outside in phase 2 of our program, now we're working on financial planning, building credit scores back.'
'We're also working on the work life stressors that come from having to enter the workforce where maybe not all the employers or colleagues you work with are as compassionate to your journey as we might be,' he said. 'It's our job to be strong enough to know how to handle it.'
Joey Mayer knows firsthand the value of getting to developing financial independence while maintaining a recovery focused community.
The 27-year-old said he's been sober just over two years and met O'Connor while a participant at the Pathway to Sobriety program at The Center, a Palos Park's religious nonprofit organization. O'Connor also found sobriety at The Center and came back to direct the program before launching the foundation.
Mayer recently moved from the Second Story Foundation's transitional home in Orland Hills to the Alsip location, where he lives with three other men in alcohol abuse recovery. While living there, Mayer works at the 9 Acres Equestrian Center stables while receiving free case management, financial planning and counseling.
'This is my first time ever having my name on a lease,' Mayer said Tuesday. 'This is like a new stepping stone for me to get adapted and acclimated to life down the road when I go to get my own home.'
Mayer said he supports the ranch model of recovery, which he believes will help others escape the isolation and dependence that is commonly developed in emergency rehab programs.
'A guy who leaves rehab and doesn't follow up on programs goes back to the same environment where he was, whether that's a basement or his room,' Mayer said. 'So I think the job and responsibility straight out of rehab is very helpful … And not only that, it gives them that breath of fresh air.'
ostevens@chicagotribune.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'
Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'

New York Post

time31 minutes ago

  • New York Post

Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'

What you do in the shower is your business, but the one thing experts are warning you to stop doing while sudsing up: peeing. One healthcare expert shared in a now-viral TikTok with over 1 million views that emptying your bladder while standing in the shower can be damaging — especially for women. Advertisement 'Hot take but don't pee standing up in the shower or anywhere for that matter. Ladies, you are training your bladder that it's okay to empty while standing. Don't do it! This could cause bladder leakage,' @kingsley.502 wrote as her caption. As expected, people ran to the comment section to share their opinions on this advice. 'My body created a human… I'm gonna let her tinkle wherever she likes,' one commenter wrote. Advertisement 'I can't even enjoy the simple pleasures in life,' shared another frustrated person. 'Meanwhile sitting for too long messes with our pelvic floor. So what actually is ok anymore?' said someone else, making a valid point. Many people in the comments of the viral TikTok video were upset to learn of this news. uduhunt – It's no surprise that this news is upsetting for many, considering almost a quarter of Americans admit to peeing in the shower regularly, according to a survey. Advertisement Unfortunately for these multitasking people, @kingsley.502 wasn't far off with her opinion on shower peeing — as other experts backed up her claims. 'It is one, not very hygienic, but more important than that, it will destroy your pelvic floor, and also it might create mental associations where you hear water running and all of a sudden you need to run to the bathroom,' Houston-based OB-GYN Emma Qureshey explained in a TikTok. And standing while peeing is not only unhealthy for women — it's also dangerous for men. Advertisement Since the pelvis and spine muscles are most relaxed when sitting, Gerald Collins, a consultant urological surgeon at Alexandra Hospital in Cheshire, England, said that 'Sitting is probably the most efficient way of doing it [peeing]' the doctor explained, Standing while urinating also puts men at risk for benign prostatic hyperplasia — which occurs when the prostate gland and surrounding tissue expand, obstructing the urethra. Sadly, for many men, the thought of sitting while peeing is looked down upon. In Germany, those who don't stand to relieve themselves are called 'Sitzpinkler' — a slur implying they are 'wimpy or effeminate.'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Business Upturn

time38 minutes ago

  • Business Upturn

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

Exclusive: Zorro clinches $20M Series A for ICHRA health plans
Exclusive: Zorro clinches $20M Series A for ICHRA health plans

Axios

time2 hours ago

  • Axios

Exclusive: Zorro clinches $20M Series A for ICHRA health plans

Health benefits provider Zorro raised $20 million in Series A funding led by Entrée Capital, CEO Guy Ezekiel tells Axios exclusively. Why it matters: As employers wrestle with rising health plan costs, individual coverage health reimbursement arrangements (ICHRAs) are gaining steam. Driving the news: Launched in 2020, ICHRAs were enabled by a Trump-era rule letting employers reimburse employees tax-free for individual health insurance instead of offering group plans. After a slow start, rule clarifications and compliance tools made them more accessible to midsized employers. Follow the money: Existing backers Pitango and 10D joined the round, which will be used to scale operations and improve support for employers. The Series A brings Zorro to $31.5 million total raised. The company is not yet profitable. How it works: New York City-based Zorro replaces traditional group plans with defined-contribution models. Employers set a budget; employees use Zorro's AI engine to select personalized plans, and brokers get real-time tools to compare group plans versus ICHRA-based options. When it onboards an employer, Zorro asks them to send their benefits roster from the previous year, asks about quality and budget priorities for the upcoming year, and helps predict what benefits employees might want next. Zorro has "several thousand" lives on the platform, per Ezekiel. Between the lines: Zorro's pitch hinges not just on cost control but on its ability to shift complex decision-making from HR to software — claiming that 75% of users enroll without human help. What they're saying: "We're giving the employer a line of sight to how his upcoming year is going to look," says Ezekiel. Reality check: While ICHRAs are gaining traction, they remain a small fraction of the employer market. Zorro's long-term success depends on widespread broker adoption and employee trust in AI-led benefit decisions. State of play: A February Bailey's report predicted the debut of several new ICHRA startups in 2025. Several others have secured recent funding. In April, Thatch raised $40 million in Series B funding led by Index Ventures and Venteur Health Insurance raised a $20 million Series A led by Informed Ventures and American Family Ventures. Remodel Health last December collected more than $100 million in a round led by Oak HC/FT and Hercules Capital.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store